Episode
Special Edition: What's Next—Cortisol, Metabolism & Future Innovation, Part 4
- Podcast
- DOC Updates
- Published
- May 19, 2026
- Duration seconds
- 1626
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/doc-updates-200053/episodes/special-edition-what-s-next-cortisol-metabolism-future-innovation-part-4/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/doc-updates-200053/special-edition-what-s-next-cortisol-metabolism-future-innovation-part-4.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Is hypercortisolism the hidden culprit in a significant proportion of both difficult-to-treat diabetes and resistant hypertension? In part 4 of our special series, Dr. Neil Skolnik speaks with John Buse, MD to explore the effects of hypercortisolism, until just recently considered a vanishingly rare condition. This special episode is sponsored with support from Corcept . Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts , Amazon Music , Spotify , or your preferred podcast platform. Presented by: Neil Skolnik , MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John Buse , MD, The Verne S. Caviness Distinguished Professor and director of the Diabetes Center at the University of North Carolina at Chapel Hill School of Medicine, a past president of medicine & science at the American Diabetes Association (ADA), and recipient of the ADA Outstanding Achievement in Clinical Diabetes Research Award Selected references: Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes . Diabetes Care April 2025 Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment . Diabetes Care June 2025 MOMENTUM: Hypercortisolism Present in 1-in-4 with Resistant Hypertension . HCP Live March 2026